Immunization Delivery Approaches
Immunization delivery approaches aim to ensure effective, safe vaccine administration across military operational environments. Emphasis is on thermostable formulations, needle‑free platforms (microneedle patches, jet injectors), mucosal/aerosol routes, and integrated logistics (cold-chain alternatives, sensors). These reduce logistical constraints and maintain protective immunity despite delayed evacuation or austere conditions.
Technical Challenges
Cold-chain dependence and vaccine thermostability limit reach in austere or prolonged-field-care environments.
Needle-based delivery risks (needlestick injury, sharps disposal) and requirement for trained vaccinators reduce rapid mass immunization capability.
Variable mucosal or aerosol delivery efficacy and reactogenicity complicate non-injectable vaccine strategies.
Regulatory complexity and lack of standardized field-stability assays slow translation of novel delivery platforms into operational use.
Emerging Opportunities
Truly thermostable vaccine formulations and dry-powder or lyophilized delivery systems validated for frontline use.
Easy-to-use, self-administered or minimally trained platforms (microneedle patches, auto-injectors) that are robust in austere settings.
Integrated sensors and validated stability biomarkers to verify potency in the field without complex laboratory support.
Standardized preclinical and clinical pathways for mucosal and needle-free technologies to accelerate DoD approval and deployment.
Current and Emerging Technologies in Immunization Delivery Approaches
Microneedle and dissolvable patch systems
Solid-state microneedle patches offer pain-free, low-burden delivery with potential for ambient stability and simplified logistics—ideal for self-administration and rapid mass immunization.
Thermostable formulations & dry-powder vaccines
Lyophilized and spray-dried vaccines, stabilizing excipients, and formulation science reduce or remove cold-chain needs, enabling storage and transport in extreme temperatures.
Mucosal, aerosol, and intranasal platforms
Targeted mucosal immunity via intranasal or aerosolized vaccines can confer frontline protection at pathogen entry sites; devices and formulations are emerging to improve dose consistency and safety.
Needle-free injectors and auto-injectors
Jet injectors, automated intramuscular devices, and single-use auto-injectors reduce sharps waste and enable administration by minimally trained personnel in mass or austere scenarios.
Integrated logistics: sensors, telemetry, and delivery drones
Cold-chain alternatives, embedded potency sensors, telemetry-enabled storage units, and autonomous delivery (drone/robotics) improve distribution speed and traceability to dispersed units.
Controlled-release implants and depot systems
Biodegradable depots and implantable delivery platforms offer sustained antigen release for prolonged protection where repeated access to care is not feasible.
Importance to Military Medicine
Force readiness and deployability
Rapid, reliable vaccination preserves unit readiness by preventing infectious disease outbreaks during deployment and training.
Prolonged and delayed evacuation scenarios
Field-stable and self-administered options enable maintained protective immunity when evacuation, resupply, or specialty care are delayed.
Austere logistics and mass-casualty response
Needle-free and thermostable solutions reduce logistical footprint and enable rapid, large-scale immunization in constrained environments.
Biodefense and outbreak mitigation
Flexible delivery platforms support rapid DoD response to emerging biological threats and mass prophylaxis without creating additional operational burdens.
Alignment with the MTEC Mission
Accelerates translation of DoD-relevant immunization technologies from prototype through field evaluation to operational use, consistent with MTEC’s mission to speed medical capabilities to Warfighters.
Leverages a broad portfolio—vaccines, delivery devices, logistics solutions—mirroring MTEC’s cross-disciplinary approach across infectious disease, prolonged care, and operational medicine.
Supports DoD priorities for readiness, austere operations, and biodefense by bridging engineering, formulation science, and clinical evaluation.
Promotes dual-use impact—military adoption accelerates civilian public-health benefits, aligning with MTEC’s commitment to benefit both Warfighters and the public.
Dual-Use (Military + Civilian) Applications
Mass immunization campaigns: Needle-free and patch technologies simplify large-scale vaccination during surge operations or pandemic response.
Outbreak and biodefense response: Rapid-deploy, thermostable vaccines and logistics reduce time-to-protection for exposed units and communities.
Rural and low-resource civilian health: Field-stable, simple-to-use platforms increase vaccine access for remote populations and disaster-affected areas.
Commercial translation: Technologies proven in military settings can transition to civilian markets, supporting manufacturing scale-up and regulatory approvals.
Explore MTEC Members with Immunization Delivery Approaches Capabilities
MTEC members bring multidisciplinary strengths—formulation science, device engineering, clinical trial networks, regulatory strategy, and manufacturing scale-up—to advance immunization delivery from concept to field deployment. Explore member profiles to identify partners with experience in thermostability testing, microneedle or aerosol platforms, logistics solutions, and DoD clinical evaluation pathways.
138 Members with Immunization Delivery Approaches capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
The Precision Vaccines Program (PVP), based in the Department of Pediatrics at Boston Children’s Hospital, is an academic research initiative dedicated to discovering and developing next-generation vaccines tailored to vulnerable populations. PVP conducts both basic and translational research to create novel vaccines and therapeutics for diseases that disproportionately affect infants, older adults, and immunocompromised individuals. The program brings together experts in vaccinology, clinical trials, immunology, molecular biology, data management, biostatistics, bioinformatics, and systems biology, fostering international collaboration among academia, government, and industry to advance precision medicine in vaccinology.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
BioPharma Connections is an independent, woman-owned consulting firm founded in San Francisco in 2007, providing strategic business development, technical operations, regulatory, product development, and commercialization support to the life sciences industry. Serving pharmaceutical, biotechnology, medical device, and diagnostic companies globally, the firm specializes in facilitating connections between organizations, service providers, CROs, CDMOs, and investors—guiding clients from concept to commercialization, with deep expertise in regulatory compliance, emerging technologies, and diverse therapeutic areas.
The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Advanced BioScience Laboratories, Inc. (ABL) is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics, and other biologic products. ABL leverages its expertise in product development, GMP manufacturing, and immunological testing to support the development of candidate vaccines and therapeutics through preclinical and clinical stages. The company is involved in producing and testing oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines.
HDT Bio is a clinical-stage biopharmaceutical company based in Seattle, developing novel technologies and products designed to harness and enhance the immune system for the treatment and prevention of cancer and infectious diseases. HDT Bio utilizes advanced immunotherapeutic platforms, including a proprietary nanoparticle delivery system, to provide safe, potent, and durable solutions that enable rapid clinical translation and personalized cancer therapies. The company's multidisciplinary team and international partnerships facilitate robust clinical development, innovative product design, and global distribution with the goal of improving patient outcomes worldwide.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Memsel is a biotechnology research and development company dedicated to enhancing health and combatting infections through advanced phage therapies and targeted delivery systems. The company aims to transform healthcare solutions across human, animal, and plant domains, addressing critical health challenges and antibiotic resistance.
Thylacine Bio is developing peptide-based antivirals for persistent respiratory viruses and emerging viral threats. Its approach uses peptides designed to inhibit viral fusion, with candidates intended to treat disease, prevent infection, and reduce transmission.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Circadian Positioning Systems
Circadian-Targeted Lighting to Reduce Fatigue-Driven Errors in 24/7 Naval Operations: Circadian Positioning Systems
Circadian Positioning Systems (CPS) is advancing personalized, circadian-targeted lighting to reduce fatigue-driven errors among sailors serving in 24/7 naval operations. Through MTEC Award No. MTEC-23-05-NMT-003, CPS is moving its technology from research and development into operational validation, assessing a tailored lighting system aboard an Arleigh Burke-class destroyer during an 11-month deployment.
Spectral AI
AI Powered Burn and Blast Wound Assessment for Combat Casualty Care: Spectral AI Inc.
With a $4.0 million MTEC award, Spectral AI is advancing a handheld, AI-powered diagnostic tool that builds on its FDA-cleared DeepView System to provide immediate, objective assessments of burn and blast wound healing potential. The MTEC-supported effort has progressed to a working prototype with potential to improve treatment decisions and military burn care.
University of Pittsburgh
High Resolution Optogenetic Therapy for Vision Restoration in Blinded Warfighters: University of Pittsburgh
MTEC-funded research at the University of Pittsburgh is advancing a promising approach to restoring vision in blinded Warfighters. Read how optogenetic therapy is bringing higher-resolution sight closer to reality.
Sibel Health
Continuous, ICU-Grade Wearable Monitoring for Far-Forward and Austere Casualty Care: Sibel Health Inc.
Sibel Health is advancing its ANNE® wearable monitoring platform to deliver continuous, ICU-grade physiological monitoring in far-forward, austere, and Arctic environments. Supported through MTEC-20-12-COVID19-Diagnostics-046 and MTEC-23-06-USAMRDC Multi-Topic-072, the effort is sponsored by USAMRDC to improve early detection, triage, and casualty care.